La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Lipocine a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Lipocine..

Lipocine (NASDAQ:LPCN) Azioni, Catena delle Opzioni

Lipocine

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

Lipocine Inc

WIIM

LPCN

Lipocine shares are trading lower. The company reported Q3 financial results.

<p>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 65.35 percent increase over losses of $(1.27) per share from the same period last year.</p>


Earnings

Earnings Beats

News

Lipocine Q3 EPS $(0.44) Beats $(0.48) Estimate

<p>Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced a license, development and supply agreement with to SPC Korea <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4291615-1&amp;h=2176293939&amp;u=http%3A%2F%2Fspcpharm.co.kr%2F&amp;a=http%3A%2F%2Fspcpharm.co.kr">http://spcpharm.co.kr</a> granting exclusive rights to market TLANDO&#xAE; in South Korea.</p>
<p>Under the terms of the distribution and license agreement, Lipocine will receive an upfront payment and is also eligible to receive certain regulatory and sales milestone payments, including a payment upon regulatory approval of TLANDO in South Korea. Lipocine is entitled to royalties on net commercial sales. Lipocine will supply TLANDO to SPC Korea and will receive a supply price. SPC Korea will assume responsibility for obtaining regulatory approval within the territory.</p>


Biotech

Global

General

Lipocine Announces Distribution And License Agreement With SPC Korea To Commercialize TLANDO In South Korea

<p>The results indicate robust central nervous system (CNS) activity of oral brexanolone, with concentration- and time-dependent post-dose changes in qEEG. These results confirm GABAA&nbsp;positive allosteric modulation and support future development of oral brexanolone in neuropsychiatric indications.</p>
<p>&quot;&ldquo;We are pleased with the qEEG results that confirm target engagement of oral bioidentical brexanolone, which suggests potential utility in treating numerous psychiatry indications, including depression and anxiety, and neurology indications such as essential tremor and epilepsy,&rdquo; said Dr. Mahesh Patel, President and CEO of Lipocine Inc.</p>
<p>&quot;These positive biomarker results and favorable safety profile support further development of oral brexanolone.&quot;</p>


Lipocine Reports Data From Its qEEG Study Of Its Oral Brexanolone, A Proprietary Bioidentical NAS Being Developed For The Treatment Of Post-partum Depression - Filing

Lipocine Announced Oral Brexanolone QEEG Results; Oral Brexanolone Well-tolerated With Minimal CND Depressant Effects

<p>Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced an exclusive supply and distribution agreement with Pharmalink <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4272507-1&amp;h=4094279648&amp;u=https%3A%2F%2Fpharmalink.ae%2F&amp;a=https%3A%2F%2Fpharmalink.ae%2F">https://pharmalink.ae/</a> to commercialize TLANDO&#xAE;, its oral testosterone replacement therapy, in the Gulf Cooperation Council (GCC) countries consisting of Saudi Arabia, Kuwait, the United Arab Emirates (UAE), Qatar, Bahrain, and Oman.&nbsp;</p>


Lipocine Announces Supply And Distribution Agreement With Pharmalink To Commercialize TLANDO In The Gulf Cooperation Council Countries

<p>Alliance Global Partners  analyst Scott Henry   initiates coverage on Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) with a Buy rating and announces Price Target of $10.</p>


Price Target

Initiation

Analyst Ratings

Alliance Global Partners Initiates Coverage On Lipocine with Buy Rating, Announces Price Target of $10

<p>Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity</p>
<p>SALT LAKE CITY, Sept. 5, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring Phase 2 data on LPCN 2401 will be presented at the Obesity Society's Annual <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4247052-1&amp;h=3963450958&amp;u=https%3A%2F%2Fobesityweek.org%2F&amp;a=ObesityWeek%C2%AE">ObesityWeek&#xAE;</a>&nbsp;conference to be held November 3 – 6, 2024 in San Antonio, TX.</p>


Lipocine Announces Phase 2 Data On LPCN 2401 To Be Presented At ObesityWeek November 3 – 6, 2024

<p>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.78) by 28.21 percent. This is a 17.65 percent increase over losses of $(0.68) per share from the same period last year.  The company reported quarterly sales of $89.565 thousand which missed the analyst consensus estimate of $290.000 thousand by 69.12 percent.</p>


Earnings Misses

Lipocine Q2 2024 GAAP EPS $(0.56) Beats $(0.78) Estimate, Sales $89.565K Miss $290.000K Estimate

<ul>
<li><strong>Met standard bioequivalence (BE) criteria Cmax, AUC0-t, and AUC0-∞</strong></li>
<li><strong>Ctrough criterion was met</strong></li>
<li><strong>LPCN 1154 was well tolerated with no sedation or somnolence events observed</strong></li>
<li><strong>On track for NDA filing, targeted by end of Q4 2024</strong></li>
</ul>


Lipocine Says LPCN 1154 Met standard Bioequivalence (BE) Criteria; Co Says On Track For NDA Filing, Targeting Q4 2024

<h3>Gainers</h3>
<ul>
<li><strong>Geovax Labs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock moved upwards by 72.1% to $1.91 during Wednesday's regular session. The company's market cap stands at $4.8 million. </li>
<li><strong>Nexalin Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares increased by 43.06% to $1.08. The market value of their outstanding shares is at $8.0 million. </li>
<li><strong>Vaxart</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) shares rose 33.45% to $0.7. The market value of their outstanding shares is at $123.8 million. </li>
<li><strong>Sunshine Biopharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock increased by 28.92% to $0.39. The market value of their outstanding shares is at $7.4 million. </li>
<li><strong>Portage Biotech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares increased by 25.0% to $0.3. The company's market cap stands at $5.9 million. </li>
<li><strong>Silk Road Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILK#NASDAQ">SILK</a>) shares increased by 23.78% to $26.82. The company's market cap stands at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>DermTech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMTK#NASDAQ">DMTK</a>) shares fell 55.2% to $0.15 during Wednesday's regular session. The market value of their outstanding shares is at $5.2 million. </li>
<li><strong>Zentalis Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares decreased by 49.95% to $4.2. The market value of their outstanding shares is at $298.2 million. </li>
<li><strong>Anitra</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) shares fell 33.51% to $0.16. The company's market cap stands at $4.4 million. </li>
<li><strong>Lipocine</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) stock decreased by 32.93% to $7.17. The market value of their outstanding shares is at $38.3 million. </li>
<li><strong>Taysha Gene Therapies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares decreased by 26.56% to $2.96. The market value of their outstanding shares is at $553.5 million. </li>
<li><strong>Virpax Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 24.9% to $0.57. The market value of their outstanding shares is at $1.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

AZTR

DMTK

GOVX

PRTG

SBFM

SILK

TSHA

VRPX

VXRT

ZNTL

12 Health Care Stocks Moving In Wednesday's Intraday Session

<p>&nbsp;Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4186705-1&amp;h=1751763964&amp;u=https%3A%2F%2Fwww.easlcongress.eu%2F&amp;a=European+Association+for+the+Study+of+Liver+(EASL)+Congress">European Association for the Study of Liver (EASL) Congress</a>&nbsp;on Saturday, June 8, in Milan, Italy. The presentation <strong>"Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy (HE) in patients with cirrhosis: a 52-week phase 2 randomized clinical trial"</strong> was presented by Arun J. Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University. The presentation is featured in the symposium "Revolutionary Advances in Liver Disease Research Unveiled at EASL Congress 2024" (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4186705-1&amp;h=3308810334&amp;u=https%3A%2F%2Fwww.hepmag.com%2Farticle%2Frevolutionary-advances-liver-disease-research-unveiled-easl-congress-2024&amp;a=https%3A%2F%2Fwww.hepmag.com%2Farticle%2Frevolutionary-advances-liver-disease-research-unveiled-easl-congress-2024">https://www.hepmag.com/article/revolutionary-advances-liver-disease-research-unveiled-easl-congress-2024</a>) highlighting significant advances in liver disease.</p>


Lipocine To Present 52 Week Results From LPCN 1148 Phase 2 Study In Late Breaking Session At EASL Congress 2024

<p>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) reported quarterly earnings of $0.66 per share. This is a 186.84 percent increase over losses of $(0.76) per share from the same period last year.  The company reported $7.50 million in sales this quarter. This is a 13.54K percent increase over sales of $54.99 thousand the same period last year.</p>


Lipocine Q1 EPS $0.66 Up From $(0.76) YoY, Sales $7.50M Up From $54.99K YoY

<p>Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver ("EASL") Congress, to take place June 5 to 8, 2024 in Milan, Italy.</p>
<p><strong>Presentation Details</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Title&nbsp; &nbsp;</td>
<td colspan="1" rowspan="1">Intervention with oral&nbsp;LPCN 1148 improves sarcopenia and hepatic encephalopathy ("HE") in patients with cirrhosis: a 52-week phase 2 randomized clinical trial</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Presenter:&nbsp;&nbsp;</td>
<td colspan="1" rowspan="1">Dr. Arun J. Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Session Title:&nbsp;</td>
<td colspan="1" rowspan="1">Late Breaker</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Session Date and Time:&nbsp;</td>
<td colspan="1" rowspan="1">Saturday, 8 June, 14:00 - 15:30 CEST</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Presentation Time:&nbsp;</td>
<td colspan="1" rowspan="1">15.15 CEST</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Location</td>
<td colspan="1" rowspan="1">Gold Room</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Abstract Number:</td>
<td colspan="1" rowspan="1">LP139</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p><strong>About LPCN 1148</strong></p>
<p>Lipocine is currently evaluating LPCN 1148 comprising testosterone laurate ("TL") for the management of decompensated cirrhosis. The Company believes LPCN 1148 targets unmet needs for patients with cirrhosis including improvements in sarcopenia and quality of life, prevention or reduction in the occurrence of decompensation events such as HE, and improvement in post liver transplant outcomes, survival, and costs.</p>


Lipocine Announces Late Breaking Oral Presentation Of Data From The Phase 2 Study Of LPCN 1148 At EASL Congress 2024

Lipocine Announces Completion Of Dosing In Pivotal Study Of Postpartum Depression Candidate, LPCN 1154

<h3>Gainers</h3>
<ul>
<li><strong>Eliem Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELYM#NASDAQ">ELYM</a>) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. The market value of their outstanding shares is at $112.2 million. </li>
<li><strong>Rallybio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) stock increased by 49.07% to $2.43. The company's market cap stands at $91.8 million. </li>
<li><strong>Alpine Immune Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALPN#NASDAQ">ALPN</a>) shares rose 36.62% to $64.27. The company's market cap stands at $4.2 billion. </li>
<li><strong>IMAC Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock increased by 22.41% to $3.44. The market value of their outstanding shares is at $3.9 million. </li>
<li><strong>Healthcare Triangle</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares rose 15.3% to $1.77. The market value of their outstanding shares is at $8.2 million. </li>
<li><strong>Lipocine</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) stock rose 15.2% to $7.5. The market value of their outstanding shares is at $39.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Aptevo Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 55.0% to $1.08 during Thursday's pre-market session. </li>
<li><strong>SILO Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 13.34% to $1.82. The company's market cap stands at $5.1 million. </li>
<li><strong>Acorda Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) shares decreased by 10.96% to $0.78. </li>
<li><strong>Cyclacel Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 10.25% to $1.84. The market value of their outstanding shares is at $2.4 million. </li>
<li><strong>AVITA Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) shares decreased by 9.98% to $13.0. The company's market cap stands at $334.1 million. </li>
<li><strong>Scinai Immunotherapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock declined by 9.79% to $0.44. The market value of their outstanding shares is at $1.9 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ACOR

ALPN

APVO

BACK

CYCC

ELYM

HCTI

RCEL

RLYB

SCNI

SILO

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Lipocine shares are trading higher after the company announced trial data showing LPCN 2401 treatment resulted in statistically significant body composition improvement in men.

Health Care

Lipocine Announced Results From A Phase 2 Trial Of LPCN 2401 Showing Significant Improvement In Body Composition Through Decreased Fat Mass And Increased Lean Mass Or Fat-free Mass In Obese Patients With At Least One Weight-related Comorbidity

Lipocine Announces Week 52 Results From LPCN 1148 Phase 2 Study In Patients With Cirrhosis; Says Met Primary And Hepatic Encephalopathy Endpoints In Phase 2 Study

<p>Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced that study enrollment is complete and the first cohort of subjects has been dosed in pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154. LPCN 1154, oral brexanolone, is being developed by Lipocine for the treatment of postpartum depression (PPD).</p>


Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Overall market sentiment has been high on Lipocine Inc (LPCN)  stock lately. LPCN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Lipocine Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LPCN!See Full LPCN ReportWhat is Stock Sentiment?Se

Is Lipocine Inc (LPCN) a Stock to Watch After Gaining 12.91% This Week?

LPCN, ADIL and CADL among pre-market losers

Lipocine (LPCN) has shared an update. Lipocine Inc. has entered into a new at-the-market (ATM) agreement with A.G.P./Alliance Global Partners to of...

Lipocine Initiates New ATM Offering, Ends Previous Agreement

Lipocine GAAP EPS of $0.66, revenue of $7.62M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Lipocine</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/"><strong>LPCN</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Lipocine reported earnings per share of 66 cents. This was above the analyst estimate for EPS of -68 cents.</li><li>The company reported revenue of $7.62 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/lpcn-stock-earnings-lipocine-for-q1-of-2024/">LPCN Stock Earnings: Lipocine Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

LPCN Stock Earnings: Lipocine Beats EPS for Q1 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;</p>



<p>Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.</p>



<p>Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.</p>



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p><strong>FibroGen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/fgen-stock-quote/"><strong>FGEN</strong></a></span>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.</p>



<p>Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;</p>



<p>One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.</p>



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p><strong>Nuvectis Pharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvct-stock-quote/"><strong>NVCT</strong></a></span>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.</p>



<p>Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;</p>



<p>The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.</p>



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Relmada Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/"><strong>RLMD</strong></a></span>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.</p>



<p>REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.</p>



<p>The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;</p>



<p>Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.</p>



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div><p><strong>Anixa Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/anix-stock-quote/"><strong>ANIX</strong></a></span>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;</p>



<p>The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;</p>



<p>The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.</p>



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div><p>Let&rsquo;s begin discussing<strong> Genenta Science</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gnta-stock-quote/"><strong>GNTA</strong></a></span>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.</p>



<p>While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.</p>



<p>The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;</p>



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div><p><strong>Affimed</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/afmd-stock-quote/"><strong>AFMD</strong></a></span>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.</p>



<p>The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.</p>



<p>AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;</p>



<p>As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;</p>



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Lipocine</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/"><strong>LPCN</strong></a></span>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.</p>



<p>As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.</p>



<p>However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;</p>



<p>What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.</p>



<p><em><strong>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks</strong>: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More</strong>: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a></em></p>



<p><em>On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> Publishing Guidelines.</em></a></p>
<div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Penny Biotech Stocks to Triple Your Investment

Lipocine (LPCN) has issued an announcement. On May 18, 2024, the Company's Board set cash bonus targets for employees, including executive officers...

Lipocine Sets Employee Bonuses and Expands Stock Plan

Lipocine GAAP EPS of -$0.56 beats by $0.22, revenue of $0.09M misses by $0.2M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Lipocine</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/"><strong>LPCN</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Lipocine reported earnings per share of -56 cents. This was above the analyst estimate for EPS of -78 cents.</li><li>The company reported revenue of $89,565.</li><li>This was 69.12% worse than the analyst estimate for revenue of $290,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/lpcn-stock-earnings-lipocine-for-q2-of-2024/">LPCN Stock Earnings: Lipocine Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

LPCN Stock Earnings: Lipocine Beats EPS, Misses Revenue for Q2 2024

Lipocine GAAP EPS of -$0.44

ADIL

AFMD

ANIX

APLD

BTOG

CADL

FGEN

GCTS

GNTA

MDIA

MGRM

NVCT

RENT

RLMD

SPRC

Press Releases

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Small Cap

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Comments

Lipocine

Lipocine (LPCN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO